All articles by Dominic Tyer (European Pharmaceutical Review) – Page 4
-
NewsTakeda eyes sustainable shipping with wind-powered sea freight
Partners with Vela for transatlantic medicine transportation using its cargo trimaran.
-
NewsMerck opens €150m climate-neutral filter manufacturing facility in Ireland
The German pharma company will create over 200 jobs at its new Blarney site in Cork.
-
NewsGSK outlines $30bn, five-year plan for R&D and manufacturing in the US
The company’s investment strategy will also encompass AI, digital technology and supply chain infrastructure.
-
NewsEuropean generics firm Zentiva sold in $4.8bn private equity deal
Prague-based pharma company is acquired by GTCR from Advent.
-
NewsWorldwide Clinical Trials appoints new CEO Alistair Macdonald
He takes over at the CRO from Peter Benton and brings experience from GHO Capital, Syneos Health and INC Research.
-
News
Pharma's UK dissatisfaction mounts as Merck & Co axes $1.3bn expansion
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
-
NewsCPHI Frankfurt 2025 prepares to open its doors
The October event at Messe Frankfurt is expected to welcome more than 63,000 pharmaceutical professionals.
-
NewsServier acquires treatment for autism genetic cause Fragile X syndrome
Deal with Kaerus Bioscience for KER-0193 could be worth $450m to the UK-based biotech.
-
NewsGilead breaks ground on AI-enabled US manufacturing hub
Says the Bay Area building’s digital infrastructure will make it one of biopharma’s leading artificial intelligence-powered centres.
-
News
Amgen to build $600m science and innovation centre in the US
The new Thousand Oaks, California facility will incorporate advanced automation and digital capabilities.
-
NewsMerck’s health business gains new Global Head of R&D
David Weinreich will also serve as its Chief Medical Officer and arrives at the German pharmaceutical group with experience from Amgen, Bayer and Regeneron.
-
NewsRoche touts ‘best-in-disease’ potential for anti-hypertensive zilebesiran
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.
-
News
AI digital twin developed to boost pharma manufacturing efficiency
The University of Cambridge and A*STAR platform aims to enhance fault detection, system monitoring and predictive maintenance.
-
NewsFDA tightens use of Pfizer, Moderna and Novavax COVID-19 vaccines
RFK Jr hits Comirnaty, Spikevax and Nuvaxovid with revised approvals for ‘high risk’ individuals.
-
NewsEuropean decentralised CAR T manufacturing consortium launched
EASYGEN is supported by EU funding andindustry partners that include Fresenius, Charles River, Cellix, Pro-Liance and TQ Therapeutics.
-
News
FDA starts publishing daily adverse event data
US regulator says the move to open up the FAERS database will help modernise its safety monitoring.
-
NewsGilead’s Kite agrees $350m deal to acquire US biotech Interius BioTherapeutics
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.
-
News
Boehringer Ingelheim signs gene therapy manufacturing deal with AnGes
The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene.
-
NewsMerck’s SpringWorks Therapeutics gains European approval for Ogsiveo
The drug is the first treatment for desmoid tumours to be approved in the region.
-
News
CSL to slash headcount by 15% and spinout its CSL Seqirus vaccines business
The Australian biotech's new operating model will also see medical and commercial functions at its CSL Behring and CSL Vifor units combined.